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Chap ter 6
INTRODUCTION
Delay ed g raft func tion (DGF) in renal trans p lantation is  an enig matic  p rob lem.
Prog res s  in the res earc h after the etiolog y  and c ons eq uenc es  of  DGF are hamp ered b e-
c aus e the c linic al c ons eq uenc es  of  DGF on long  term g raft func tion are unc lear and renal 
b iop s ies  are us ually  not taken to doc ument the c aus e of the DGF s y ndrome b ut rather to 
ex c lude additional ac ute rejec tion ep is odes . Our know ledg e on DGF is  mainly  b as ed on 
s tudies  in ex p erimental animals  and on c linic al data on ac ute renal failure in nativ e kid-
ney s . This  c omp aris on has  major fl aw s , b ec aus e the ris k fac tors  and c linic al s etting  for ac ute 
renal failure in the trans p lantation s etting  are s ub s tantially  dif ferent from the ris k fac tors  
for ac ute renal failure in nativ e kidney s . 
The interes t in DGF has  inc reas ed w ith the inc reas ed us e of marg inal donors , inc luding  
non-heart- b eating  donors , donors  at the ex tremes  of  ag e, and donors  w ith hy p ertens ion 
and diab etes , in order to res olv e the s hortag e of  kidney  donors . This  g roup  of  donors  ex p e-
rienc e DGF more freq uently , w ith an inc idenc e of up to 5 0 %  ( 1 -6). 
The underly ing  mec hanis m is  c ons idered to b e related to is c hemic  and rep erfus ion da-
mag e, w hic h may  b e further c omp lic ated b y  an inc reas ed likelihood of ac ute rejec tion ep i-
s odes  ( 3 ,7 )  or drug - related nep hrotox ic ity  ( 8 ) .
There is  deb ate on the imp ac t of  DGF on late g raft outc ome. Some authors  rep orted an 
ef fec t of  DGF on renal allog raft s urv iv al (9,1 0 ,1 0 ) ,w hile others  only  found inferior g raft s ur-
v iv al in p atients  w ho als o ex p erienc ed ac ute rejec tion ep is odes  ( 1 1 ,1 2 ) . 
One p os s ib le ex p lanation for this  ap p arent dif ferenc e in outc ome may  b e the defi nition of 
DGF that is  us ed. To s tudy  ris k fac tors  for DGF and its  c linic al c ons eq uenc es , it is  therefore 
v ery  imp ortant to us e a defi nition of DGF, in w hic h the c ontrib ution of is c hemia and rep er-
fus ion injury  is  s tres s ed.
Defi nition of DGF
In mos t s tudies  DGF is  defi ned as  the need of dialy s is  treatment in the fi rs t w eek after renal 
trans p lantation. This  is  a c riterion that is  eas y  to reg is ter and to ob tain from larg e datab a-
s es  ( 1 3 ) . How ev er, dialy s is  during  the fi rs t w eek after trans p lantation is  als o p erformed for 
other reas ons  than DGF, like hy p erkaliemia and /  or fl uid ov erload. Another fl aw  in this  
defi nition is  the inab ility  to ex c lude ac ute rejec tion and c alc ineurin tox ic ity  as  an additional 
c aus e of imp aired g raft func tion. For that reas on others  hav e defi ned DGF as  a func tional 
p arameter dis tinc t from the need of dialy s is  and us ed the time needed to ac hiev e an arb i-
trarily  defi ned c reatinine c learanc e as  a marker for delay ed g raft func tion (9),( 3 ,1 4). Us ing  
this  defi nition they  found an imp ac t of  DGF on s hort term g raft s urv iv al and func tion, w hen 
DGF las ted for at leas t 1  w eek and rejec tion ep is odes  w ere ex c luded. 
Bec aus e the p athog enes is  of  DGF is  s up p os ed to b e of  is c hemic  orig in w e p rop os e to de-
fi ne DGF in c linic al s tudies  retros p ec tiv ely  on the b as is  of  renal func tion, dis tinc t from the 
need of dialy s is  treatment. Us ing  the ab s enc e of a s p ontaneous  dec reas e of s erum c reati-
nine of more than 1 0 %  p er day  for at leas t 3  c ons ec utiv e day s  w ithin 1  w eek after trans -
p lantation, ex c luding  ac ute rejec tion, and c alc ineurin inhib itor tox ic ity  as  a p os s ib le c aus e 
of this  DGF, allow s  a more meaning ful analy s is  of  the ris k fac tors  and c ons eq uenc es  of  
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ischemic damage and associated reperfusion injury that is supposed to be the underlying 
cause of DGF.
Acute ischemic renal injury and recovery
In the pathogenesis of acute ischemic failure 3 stages can be recogniz ed (15). The fi rst 
stage is the ischemic phase in which ischemic and reperfusion injury takes place and in 
which renal epithelial and endothelial cells are subjected to lethal insults leading to apop-
tosis and /or necrosis (16). The main t en an ce phase represents a phase of stabiliz ation of 
injury by intrinsic or upregulated defense mechanisms. During this phase, events leading 
to cellular repair, proliferation and redifferentiation. lead to the r eco v er y  phase in which 
epithelial en endothelial function improve, leading to the recovery of renal function.
1. Ischemic phase of ATN
Ischemia and reperfusion injury in acute tubular necrosis (ATN)
During the ischemic phase, renal metabolism is characteriz ed by severe ATP depletion due 
to a lack of oxygen and a subsequent shift from aerobic to anaerobic metabolism (Fig 1.) 
(17). This leads to a disruption of cellular homeostasis, resulting in failure of the cellular 
sodium-potassium pumps as well as the calcium pumps (18). (19). Because of an increase 
in cytosolic calcium levels calcium dependent enz ymes like cystein proteases, phospholi-
pases and endothelial nitric oxide synthetase (e-NOS) will be activated (20). These enz ymes 
are able to break-down the cytoskeleton of the cells, eventually leading to cell death. Next 
to this purely ischemic condition, hypoxanthine is formed from xanthine which are degra-
dation products of adenosine triphosphate (ATP) (21). 
After the reinstitution of perfusion several factors contribute to the further damage. First 
of all the sudden increase of perfusion pressure causes endothelial damage and infl am-
mation. Next molecular oxygen (O
2
) is reintroduced, during reperfusion, which reacts with 
hypoxanthine which forms Reactive Oxygen Species (ROS). The free radical members of 
ROS are Superoxide (.O
2
) and the hydroxyl radical (.OH) and are probably the most impor-
tant biologically active free radicals, leading to extensive damage of the cell membranes 
by affecting its integrity. These processes eventually result in cellular apoptosis and / or 
cell death (22-24),(25). The cellular characteristics of this ischemic phase consist mainly of 
apoptosis and necrosis.
Apoptosis or programmed cell death is an active, energy dependent process with mor-
phological characteristics that differ markedly from necrosis. The essence of apoptosis is a 
process of cellular auto-digestion, which is regulated by activation and inhibition of enz y-
mes and which are identical for all human tissues. The key molecules are proteases named 
caspases of which the caspase-3 is the enz yme that is the end of the fi nal common path 
way (Fig.2). Upon activation of caspase-3, DNA is fragmented leading to the characteristic 
apoptotic bodies. Because of subsequent changes in the plasma membranes, the cells are 
removed by phagocytic cells.
Necrosis is seen in experimental animal models but only in a minority of the human cases 
(26-28). It is usually patchy involving individual cells or small clusters of cells sometimes re-
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sulting in small areas of denuded basement membrane (non-replacement phenomenon). 
Tubular cell necrosis is associated with a rapid metabolic collapse, cell swelling and early loss 
of plasma membrane integrity and the loss of the polarity and the integrity of their tight 
junctions is disrupted, perhaps as a consequence of alterations in the cytoskeletal network 
(18,29). Because of the redistribution of the Na/K -ATPases, tubular function is disturbed and 
cells die. This in turn leads to the release of proteolytic enzymes and other injurious cytosolic 
components into the extracellular space that incites an infl ammatory response. M ore subtle 
changes include loss of brush border, fl attening of the epithelium, detachment of cells, intra-
tubular cast formation and dilation of the tubules (26-28) (Fig. 3).
Figure 1. Schematic representation of the apoptotic cascade
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Figure 2 . Schematic representation of the ischemia and reperfusion injury cascade
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2. Maintenance phase of ATN
The kidney has naturally present anti-oxidant enzymes to counteract the effects of the free 
radicals. The catalases and gluthathion peroxidase act by safely decomposing the peroxi-
des. The superoxide dismutases (SOD) act by scavenging the free radicals especially the 
.
O
2
.
In humans it is present in at least two forms, the cytoplasmatic copper/zinc (CuZ n)-SOD and 
the mitochondrial manganese (Mn)-SOD. SODs are enzymes that catalyze the dismutation 
of
.
O
2
 to hydrogen peroxide (H
2
O
2
), which is decomposed, by other enzymes like catalase 
and gluthation peroxidase (22). The presence and the (down regulated) activity of these 
SOD’s seem to be related to the amount of damage induced by ROS in rat kidneys (30,31). 
However, the clinical use of human recombinant superoxide dismutase, did not protect 
against DGF in human kidneys (32,33). During the maintenance phase tubular cells share 
characteristics of the ischemic phase in which necrosis, apoptosis and the interstitial in-
fi ltrate are present and characteristics of the recovery and regeneration phase in which 
proliferation and redifferentiation are present.
Figure 3. Cell biological characteristics of the acute tubular necrosis 
Reprinted with permission (98)
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3. Recovery phase of ATN
This process is regulated by the expression of a number of transcription factors, structural 
proteins and growth factors and is a copy of kidney organo-genesis in respect to the high 
rate of DNA synthesis, like PCNA, the expression of apoptosis and the expression of ge-
nes that encode for processes during renal organogenesis like keratin and vimentin (34) 
(35,36). On ischemia and reperfusion injury growth factors like the hepatic growth factor, 
insulin like growth factors and fi broblast growth factors are upregulated (37,38). Others 
such as epidermal growth factors are down regulated in injured proximal tubules (39). Tre-
atment with these growth factors in animal models was promising (37,40,41) but the use in 
humans is still limited (42). During recovery from ischemia and reperfusion injury, surviving 
tubular epithelial or renal stem cells, differentiate and proliferate, eventually replacing the 
irreversibly injured tubular epithelial cells and restoring tubular integrity (43,44). Morpho-
logically this is characterized by the presence of mitotic fi gures and signs of cell prolifera-
tion. This process enables the replacement of the damaged epithelium and is maximal at 
24 to 48 hours after ischemic injury in the rat. (45).
Risk  factors of DGF
Using the earlier-mentioned functional defi nition of DGF, risk factors for post transplant 
acute renal failure (DGF) can be divided in donor-related factors, transplantation-related 
factors and recipient related risk factors. The cadaveric kidney is theoretically subjected 
to the cumulative damage at every step along the way from procurement to reperfusion 
whereas kidneys from living donors rarely develop DGF.
Risk  factors related to the donor 
Well known donor related risk factors for DGF are donors of over 50 years of age and an 
elevated serum creatinine or suboptimal renal function of the donor. In human adults, renal 
blood fl ow (RBF) declines by approximately 10% per decade after the age of 40. This reduc-
tion of RBF is partially explained by a reduction of renal mass but is accompanied by an in-
creased afferent and efferent arteriolar resistance especially in the renal cortex (46,47). This 
change in glomerular fi ltration rate (GFR) is hard to detect when serum creatinine alone is 
taken into account: Muscle mass and consequently urinary creatinine excretion, decreases 
with age. This implies that for the same serum creatinine concentration, GFR in the elderly 
can be severely impaired in comparison to younger adults. Kidneys from older individuals 
have several structural and functional changes compared with kidneys from younger do-
nors. Longitudinal studies of elderly individuals have shown a diminution in renal reserve, 
along with functional constraints on the kidney’s ability to respond appropriately to chal-
lenges of either excesses or defi cits (48). Studies of kidneys obtained at autopsies demon-
strated a progressive decrease in the number and size of glomeruli with age, resulting in a 
progressive decrease of the glomerular fi ltration volume (49,50). In addition to the loss of 
glomeruli, there is an age-dependent increase in the cortical interstitial volume as a result 
of progressive interstitial fi brosis (49,51). Most renal biopsies from kidney donors who are 
older than 40 yr show intimal fi brosis in the smaller arteries, arteriolar hyalinosis, and inter-
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stitial fi brosis (52). Not only factors intrinsically related to the donor, but also events prece-
ding brain death and harvest of the kidney contribute to the occurrence of DGF. Before the 
establishment of brain death of the potential donor, the kidney may be damaged by the 
underlying disease process (e.g. hypotension or shock), or by the therapeutic maneuvers 
instituted in an attempt to revive the patient or to maintain circulation after brain death, 
like the use of dopaminergic medication and resuscitation procedures (53). Decreasing pla-
telet count and disseminated intravascular coagulation are frequently found and at least 
suggest that endothelial injury or dysfunction may already be present before the organs 
are harvested. During episodes of cardiac arrest or prolonged hypotension, the kidney will 
suffer from warm ischemia and reperfusion injury. Catecholamine release and pharmaco-
logical inotrope agents may contribute to intrarenal vasospasms leading to areas in the 
kidney subjected to relative hypoperfusion. Because the donor generally is in a catabolic 
state, recovery from ischemic damage is more diffi cult. After brain death but before explan-
tation, the potential donor may not be considered a high priority for surgery in the setting 
of a busy intensive care unit and resuscitation may be delegated to those with limited ex-
perience in appropriate care (54). 
Risk factors related to the transplantation procedure
Organ procurement also contributes to the development of DGF. This starts with hypoper-
fusion after circulation of the donor has stopped (warm ischemia time [ WIT]). However, 
with the multi organ procurement procedures currently this WIT is almost reduced to zero. 
However, with the raising interest of non-heart beating procedures, WIT has nowadays be-
come a serious contributor to DGF (55), (56). During surgery errors in line placement can 
result in inadequate fl ushing of blood and / or cooling, and undue manipulation of renal 
arteries can induce vascular spasm (53). The most important independent and robust risk 
factor is the time that it takes from the explantation of the kidney until its transplantation 
into the recipient , defi ned by the cold ischemia time (CIT) (57-63). The type of preservation 
fl uid also is recognized as a risk factor for DGF in a study in the Eurotransplant area, in which 
the preservation fl uid developed by the University of Wisconsin (UW) appeared to be su-
perior to Euro Collins (EC) (64). After perfusion is reestablished several mechanisms exist 
that can damage the renal allograft including the generation of free radicals, mechanical 
injury to blood vessels from sudden high blood fl ow, vasomotor derangement from prosta-
glandins and other regulatory peptide imbalances and cytokine release from infl ammatory 
infi ltrates (65).
Risk factors related to the recipient
Recipient age is a risk factor for DGF especially when kidneys from pediatric donors to adult 
recipients are involved (6). The relation between the occurrence of DGF and the discrepan-
cy between donor and recipient Body Mass Indexes (BMI) supports this hypothesis (66). 
The lower occurrence rate of DGF with zero HLA mismatch and low levels of panel reactive 
antibodies (PRA) (67), suggests that immune factors are responsible for this relation. Be-
cause the studies that describe this effect, used dialysis treatment in the fi rst week as their 
defi nition of DGF, it is conceivable that early acute rejection activity constitutes the missing 
link (4,6,60). In addition, the use of calcineurin inhibitors is a riskfactor because their vaso-
constrictive properties infl uence renal perfusion and enhance ischemic damage (68).
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 Finally abnormalities in the calcium and phosphate metabolism are not uncommon in 
patients on the waiting list for a renal transplant. For instance secondary hyperparathyroi-
dism has been associated with a higher incidence of DGF (69,70). But studies on the effect 
of hypercalcemia and hyperparathyroidism in renal transplants are lacking.
DGF and long-term graft survival
The effect of DGF on short and long term patient and graft survival is unclear. Some aut-
hors reported an effect of DGF on graft survival (6,71) while others did not or only found 
this effect when it coincided with the occurrence of acute rejection episodes (72). Recent 
data on the outcome of grafts from non heart beating donors have shown, that if strict se-
lection criteria were applied with respect to donor age, warm ischemia time and duration 
of oliguria of the donor, long term graft survival was good, despite the high incidence of 
DGF (2). Brook et al (1).found that when long term graft survival of grafts from heart bea-
ting donors (HBDs) experiencing DGF are compared with grafts from non heart beating 
donors (NHBDs) with DGF, graft survival after 6 years of follow up is even better in the 
NHBD group 
When the survival curves are closely analyzed it is striking that 1 year after transplantation 
the survival curves run parallel. This suggests that DGF has its effect in the fi rst year post-
transplantation, but has no negative impact on graft survival beyond the fi rst year. This 
fi nding is supported by studies that analyzed risk factors on graft survival after 1 year and 
found that progression of chronic graft failure was mainly associated with donor age, cre-
atinine clearance, proteinuria and the presence of hypertension in the recipient and not 
with the occurrence of DGF per se (73).
DGF and renal function
One of the enigmatic problems of DGF is why some grafts react with DGF and others do 
not whereas the risk profi les are comparable Furthermore the effect of DGF on long term 
graft survival is unclear.
S lope and intercept
We proposed a theory on the course of graft function after transplantation. We presumed 
two variables to be important in the fi nal evolution of graft function over time. The inter-
cept determines the boundaries within which graft function develops. We suppose that this 
intercept refl ects the quality of the transplanted organ. The slope exemplifi es the long term 
course of graft function. Using this concept we analyzed renal function of 654 patients that 
were transplanted between 1983 and 1997. The creatinine clearance at 6 months was used 
at the determinant of the intercept of the graph that describes graft function over time 
and was categorized as more or less than 50 ml/min. Chronic decline in function, modeled 
by one or two least square fi tted regression lines after 6 months, was determined as a ne-
gative slope signifi cantly different from zero. We created four patterns of evolution of graft 
function over time (Fig 4). 41% of grafts resumed and maintained optimal function post im-
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plantation (creatinine clearance >  50 ml/min) whereas 28 % achieved a similar function but 
experienced function deterioration afterwards (negative slope) The remaining 31% had a 
creatinine clearance at 6 months of <  50 ml/min, of which half maintained stable function 
and the remaining grafts displayed progressive loss of function. Using logistic regression 
analysis we found that old donors and female gender of the donor, histoincompatibility 
,the incidence of delayed graft function and the incidence of acute rejection episodes in 
the fi rst 6 months were independent risk factors for a low intercept, whereas younger reci-
pient age, previous sensitization, class I histoincompatibility, baseline immunosuppression 
and late acute rejection episodes were associated with a negative slope. In the multivariate 
analysis proteinuria and diastolic blood pressure at 6 months were determinants of graft 
function deterioration. We also found that the rate of deterioration is dependent on graft 
function at 6 or 12 months (73), in which grafts with a function of <  50 ml/min that deteri-
orate have a faster decline in renal function than grafts with a creatinine clearance of over 
50 ml/min.
DGF and short term and long term graft function
In a recent study (3), we analyzed the risk factors and the impact of DGF on graft loss and 
renal function. DGF was diagnosed, when serum creatinine level increased, remained 
unchanged or decreased less than 10% per day immediately after surgery during three 
consecutive days for more than one week excluding acute rejection when anti rejection 
treatment was started within this fi rst week. Grafts that never functioned, ultimately lea-
ding to graft nephrectomy, were also excluded, because this is most often caused by sur-
gical complications like renal vein or artery thrombosis or by hyperacute rejection. The 
incidence of DGF was related to a donor age of more than 50 years (odds ratio [OR] 2.21; 
confi dence interval [CI]:1.49-3.26), cold ischemia time (CIT) of more than 28 hours (OR 1.78; 
CI:1.19-2.63), mean arterial pressure (MAP) of the donor of less than 100 mmHg (OR 2.08; 
CI:1.43-3.03) and the transplantation of a female donor kidney to a male recipient (OR 1.55; 
CI:1.15-2.55).
Analyzing the impact of DGF on graft survival and graft function we found that DGF was 
associated with a suboptimal 1 year graft function but neither with inferior long term nor 
short term graft survival. Suboptimal graft function after 1 year, defi ned as a serum crea-
tinine clearance of less than 50 ml/min was apart from the incidence of DGF associated 
with risk factors that can be classifi ed as non-immunological [donors over 50 years of age 
Figure 4 
Six hundred and four transplants catego-
rized according to intercept (endogenous 
creatinine clearance at 6 months) and slo-
pe of reciprocal creatinine concentrations 
beyond six months post-transplant (73)
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(OR 2.39; 95% CI: 1.61-3.57) or female donors (OR 1.99; 95% CI: 1.42-2.78)] and immuno-
logical (more than 1 acute rejection episodes in the fi rst year [OR 2.66; 95% CI: 1.87-3.78], 
peak panel reactive antibody level of more than 50% [OR 1.67; 95% CI: 1.15-2.47] and the 
number of shared Cross reactive groups major histocompatibility complex class I antigens 
(CREG ) [OR 1.65; 95% CI: 1.09-2.49]. Long term graft survival was related to graft function 
at one year and the number of acute rejection episodes or treatments during this fi rst year 
(Fig.5).
Tubular Function Slope (TFS) in MAG-3 renal scintigraphy 
To analyze the underlying functional mechanisms of DGF, we studied a group of 28 pa-
tients with immediate graft function (IGF) and 14 patients with DGF, with 99mTechnetium-
mercapto-acetyltriglycine (MAG-3) renography. The renal handling of MAG-3 is equivalent 
to paraminohippurate (PAH) (74). We defi ned TFS in a background subtracted MAG-3 graft 
curve: the fi rst 2 minutes consist of a rapidly ascending phase as a result from initial per-
fusion and a second phase representing the tubular extraction phase. The slope of this 
second phase was defi ned as the tubular function slope TFS (Fig.6 ). Because this can only 
be done by active proximal tubular cells we used this TFS as a marker for functional renal 
mass. We found that all grafts had an initial recovery phase of the TFS from the moment 
of transplantation until a maximum level was reached after 3 to 4 weeks, indicating that 
initial damage from the transplantation procedure was comparable in both groups and 
that both groups recovered equally. However, in absolute terms, grafts with Immediate 
Graft Function (IGF) always had a higher TFS as compared with grafts with DGF and this 
difference persisted until the end of follow up at 3 years after transplantation. When cre-
atinine clearance was analyzed for these grafts there also was a clear difference between 
the groups, but this did not reach the level of statistical signifi cance (14). These fi ndings 
suggested that grafts with DGF have an initial lower functional renal mass than grafts with 
IGF. Unfortunately this could not be translated in a difference in renal function, because of 
a lack of power of this study.or lack of accuracy in renal function estimation.
Figure 5. Graft survival according to graft 
function 1 year after transplantation. 
Kaplan-Meier estimates for transplants ex-
periencing a 1-year creatinine clearance of 
>50 ml/min (solid rule N=  339); 40-50 ml/
min (short dashed rule N=  135); 30-40 ml/
min (long dashed rule N=  79) < 30 ml/min. 
(long, short, long dashed rule N=  56)(3) Time  post-transplant, years
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Figure.7 Creatinin clearances of 
grafts w ith and w ithout D GF du-
ring Þ  ve years follow - up.
a: At 3,6,12,24 and 60 months grafts expe-
riencing DGF had lower creatinin clearances 
than grafts that did not.
b: After correction for the initial TFS value, the 
curves were superimposable.
( dashed rule ,IGF ;solid rule, DGF).
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a: V alues of the tubular function slope (T FS)  
in the groups w ith and w ithout D GF (14). Af-
ter correction for the initial TFS value, the curves 
were superimposable, (p = 0.85) indicating that 
the differences between the two groups were 
determined by the differences already present in 
the early post transplant 99mTc-MAG3 renograp-
hies ( dashed rule, IGF ;solid rule, DGF).
b: Creatinine clearances at 3,6 ,12 and 36  
months after transplantation. The values ten-
ded to be lower in patients that experienced DGF 
but did not reach statistical difference ( dashed
rule, IGF ;solid rule, DGF).
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Therefore we expanded the groups with a population of seven hundred and ninety reci-
pients of cadaveric renal transplants in the era 1983 until 1997 from a former study and 
analyzed creatinine clearances in a the IGF group and DGF group during a 5 years follow 
up period. This analysis confi rmed that grafts with DGF had lower creatinine clearances 
than grafts that experience IGF, which was present during the whole period of follow-up 
(p < 0.0001). After correction for the initial difference in creatinine clearance between the 
2 groups, the curves show a identical pattern over time (p = 0.58). There was a decrease in 
creatinine clearance at 5 years follow up, which was mainly present in the IGF group. The 
relatively better results in the DGF group at 5 years are presumably caused by the lower 
number of grafts in the DGF group after 5 years, and the loss of badly functioning grafts at 
that moment (Fig.7)
Vulnerability and DGF
Damage versus protection
The MAG-3 study gave us insight in the possible role of DGF in long-term graft function. We 
found that all grafts irrespective whether they develop DGF or not, experience an episode 
shortly after transplantation of impaired tubular extraction of MAG-3 that recovers within 
3 weeks. This initial deprivation is caused by ischemia and subsequent tubular dysfunction, 
apoptosis and necrosis characteristic for the initiation phase of acute tubular necrosis (15) 
and are identical for grafts with and without DGF. However, the reason why a graft responds 
to this initial peri-transplantation injury with anuria, remains to be explained: Kidneys have 
a capacity to resist or to recover from ischemic or chemical induced tubular necrosis. These 
protective and repair mechanisms are characteristic for the maintenance and recovery 
phase of acute renal failure in native kidneys. Well known enzymes that are involved in 
tissue protection against ischemia and reperfusion injury are the (SODs)(75) and the he-
moxygenase-1 (HO-1)(76,77). Theoretically grafts experiencing DGF have less protective 
and recovering capacity and therefore are more vulnerable to ischemic damage. A possible 
explanation for the difference between grafts reacting with DGF and grafts with immediate 
graft function lies in their ability to protect itself against ischemic and other damage during 
the whole transplantation procedure.
We therefore compared the expression of superoxide dismutases between grafts with and 
without DGF. We found that when manganese SOD was present, DGF occurs less frequent-
ly (Fig 8), whereas the presence of Cupper/Zinc and extra-cellular SOD had no effect. No 
relations were found between the incidence of the histological presence of ATN and the 
occurrence of DGF. However the presence of ATN correlated with a more extensive pre-
sence of active caspase-3 staining. These fi ndings support the idea that the way a kidney 
reacts on ischemia and reperfusion injury depends on the quality of the transplanted tis-
sue, which is represented by its protective enzymes. However, clinical trials with the use of 
rh-SOD in humans have been disappointing with respect to the incidence of DGF (32,78). 
Nevertheless a protective effective effect of treatment with Rh-SOD on long-term graft sur-
vival was found(78). Also a protective effect of hemo oxygenase-1 (HO-1) in rats has been 
found in vivo models with rats (79,80). 
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Calcium and calcium channel blockers and DGF
The role of calcium channel blockers in the protection against DGF is controversial (81-85). 
The protective role of CCB’s against DGF is thought to be due to its vasodilatory capacity, 
which counteracts the vasoconstrictive effects of the calcineurin inhibitors, cyclosporine 
A or tacrolimus. Disturbance of calcium homeostasis is important in the pathogenesis of 
ATN. 
Cytosolic calcium is a co-factor in the activation of cystein proteases like calpain and ca-
spase-3 (86-88), enzymes that have an important role in the process of ATN. Acute renal 
failure in native kidneys has been reported in patients with serum calcium levels above 3.5 
mmol/L. In native kidneys, acute renal failure due to hypercalcemia is describer in the milk 
alkali syndrome (89), severe hyperparathyroidism or PTH-related proteins (PTHrP) associa-
ted conditions(90) or multiple myeloma (91) and vitamin D intoxication (92). Little is known 
about the effects of hypercalcemia on the initial function of renal allografts. Torregosa et al. 
and Traindl et al. (69,70) reported a signifi cant effect of elevated PTH levels on the incidence 
of DGF, whereas serum vitamin D levels and serum calcium levels did not differ between 
the group with immediate graft function and the group with DGF.
The underlying mechanism explaining how calcium causes acute renal failure remains un-
resolved, but nephrocalcinosis may play a role. In animal models 3 types of nephrocalci-
nosis can be distinguished: chemical nephrocalcinosis, microscopic nephrocalcinosis and 
macroscopic nephrocalcinosis (93). The latter is characterized by gross calcium deposits 
found on radiographic investigations. Microscopic nephrocalcinosis is characterized by 
microscopic calcium deposits, mainly located in the lumen of the tubules. It is supposed to 
be a transitional phase between chemical and macroscopic nephrocalcinosis. Microscopic 
nephrocalcinosis is associated with increased calcium x phosphate product and with chro-
nic renal failure. Its effect on renal function is thought to be caused by tubular obstruction 
and tubular back-leak. Chemical nephrocalcinosis, assumed when macroscopic and mi-
croscopic are excluded, affects glomerular fi ltration rate by vasoconstriction and natriuresis 
Figure 8 
Distal tubular localization of Mn SOD in the presence (A) and absence (B) of DGF. Note the increased 
staining intensity of Mn SOD (red) in biopsies with DGF (right arrow). (Counter staining: anti-cubu-
lin (brown), identifying the brush border of proximal tubules. p, proximal tubules; d, distal tubules. 
Original magnifi cation: 400x) 
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induced volume constriction (94).It is histological characterized by areas of focal necrosis 
in the distal tubules and medullary collecting duct. High calcium content of the medullary 
area was found and the functional substrate was characterized by impaired function of 
the distal tubules. The role of cytoplasmatic calcium as an intracellular messenger in many 
important cell functions might explain these functional changes associated with the high 
cytoplasmatic calcium content. Calcium dependent enzymes that were analyzed in vitro in 
this respect are the cystein proteases, like calpaine and the caspases (20).
We therefore performed a study in which we analyzed the role of hypercalcemia in the 
occurrence of DGF. Serum calcium levels were correlated with the incidence of DGF in rela-
tion to other well known risk factors for DGF like donor age and cold ischemia time Further-
more the presence of calcium deposits in renal biopsies were correlated with the presence 
of DGF and serum calcium levels.
We found that hypercalcemia was an independent risk factor for DGF and that the pre-
transplant use of calcium channel blockers had a protective effect on the incidence of DGF. 
DGF was not associated with the presence of calcium deposits in renal biopsies, suggesting 
calcium infl uences tubular function by chemical nephrocalcinosis (95). This also suggested 
that the protective effect of calcium channel blockers is not only due to the formerly men-
tioned mechanisms but also by the prevention of the uncontrolled infl ux of calcium into 
tubular cells and subsequent activation of cystein proteases.
DGF as a herald rather than a risk factor for poor long term outcome
DGF in renal transplantation is a syndrome that is caused by ischemia and reperfusion in-
jury. This syndrome of acute renal failure is a result of the interaction between the defense 
mechanisms of the graft on the one hand and the ischemic insults during the whole trans-
plantation procedure on the other hand. Because these ischemic insults do not fully ex-
plain the graft’s reaction upon transplantation, the differences in the defense mechanisms, 
which can be translated as differences in quality of the graft, probably are the key to the 
explanation why a graft reacts with DGF or not.
The often found relation between DGF and poor graft outcome therefore should also be 
explained in this scope of differences in quality of the graft, rather than that DGF is an 
independent risk factor for long-term graft outcome. The following fi ndings support this 
hypothesis: First of all, we found that DGF was associated with a low intercept rather than 
with a negative slope in the curves that describe the evolution of graft function over time. 
Furthermore we showed during a follow up of 5 years that grafts from heart beating donors 
(HBD) reacting with DGF have an inferior long term graft function than grafts that do not 
react with DGF. Because this discrepancy was already present shortly after transplantation, 
we presume that differences in graft quality are also responsible for this phenomenon. The 
quality of the graft in essence determines, the full functional potentials of the graft which 
are determined by traditional risk factors for DGF, of which donor age and donor gender 
are important determinants. We found other arguments for our hypothesis in a MAG-III 
renography study in which a determinant of the functional renal mass, the tubular function 
slope (TFS), was found to be signifi cantly lower during a follow up period of 3 years, in 
the DGF group compared to the non-DGF group. This difference was also already present 
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shortly after transplantation. In an immuno-histochemical study we found a higher tissue 
expression of Mn SOD, a protective enzyme against ischemia and reperfusion injury and a 
possible marker of graft quality, in grafts experiencing immediate function. 
Other risk factors like cold ischemia time, brain death of the donor, the use vaso-active 
agents in the procurement of the donor and warm ischemia time represent the amount 
of ischemic insults that the graft must resist. When these ischemic insults are large enough 
also a graft with a good quality ultimately will react with DGF. However when the graft 
overcomes this insult, its function should recover to a level that corresponds with its in-
trinsic quality. Findings in non-heart beating donations (NHBD) in which warm ischemia 
is prolonged as a representative of the intensifi ed ischemic insults, illustrate that unless a 
high incidence of DGF, long term graft function and survival is equal in the NHBD and HBD 
group. Strikingly in the NHBD group donor age was lower and male gender more frequent. 
This may explain the comparable outcomes between the two groups, because this is de-
termined by organ quality is guaranteed (1,2). In heart beating donations we showed that 
the difference in function expressed as creatinine clearance between grafts experiencing 
DGF or not, is already present shortly after transplantation. Therefore it is not amazing that 
grafts experiencing DGF have a lower function during follow up. This means that DGF is an 
expression of poor quality rather than a cause of this graft deterioration.
Conclusion
DGF in renal transplantation is a syndrome that depends largely on the quality of the trans-
planted organ. Because the number of nephrons or the functional renal mass that is trans-
planted is determined at the time of the transplantation, the frame work within which graft 
function develops is set in the early post-transplant period. This functional renal mass is 
determined by factors like donor age and donor gender and this explains why these tradi-
tional risk factors are related with graft outcome. The occurrence of DGF is determined by 
the balance between ischemia reperfusion injury on the one hand and the functional renal 
mass and its protective mechanisms on the other hand. 
Renal function is inversely correlated with the incidence of cardio vascular events and the 
main cause of patient death on hemo- and peritoneal dialysis is cardio vascular disease, 
this is of extreme importance in our search to solve the problem of organ donor shortage. 
Despite increased donor awareness and actions, the actual number of organ donors has 
not increased to any meaningful extend. This disparity has led to an increased interest in 
the use marginal donors, including donors at the extremes of age, donors with a history 
of hypertension or diabetes and non heart beating donations. To use these donors in an 
appropriate way in order to achieve a high percentage of transplantation in patients with 
end stage renal disease and above all good graft function, the quality of the graft should be 
assessed at the time of donation. Separate from a strict risk stratifi cation in the case of non 
heart beating donation (96) and the use of histo-morphological criteria (97), measurement 
of MnSOD in the pretransplant biopsy might be of additive value to determine the quality 
of the graft. After having assessed this quality to some extend the ischemic insults to grafts 
with inferior function should be minimized. This can be done by minimizing the ischemic 
insults limiting cold and warm ischemia time and the use of a proper immunosuppressive 
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regimen. The peri-operative use of calcium channel blockers within the framework of is-
chemia reperfusion injury should be reevaluated. On the other hand interventions should 
be developed to augment the intrinsic resistance against ischemic reperfusion injury. The 
application of protective enzymes like manganese Super Oxide Dismutase (Mn-SOD) and 
Heme-Oxygenase-1 (HO-1) should be considered.
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